ADLM (formerly AACC)

Alvaro González

Alvaro Gonzalez

Dr. Alvaro González, Ph D

Full professor of Biochemistry. Head of the Department of Biochemistry. Clinica Universidad de Navarra.

Works in liquid biopsy in the last two years:

  • Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A. Quantitative cell-free circulating BRAFV600E mutation analysis using droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 2015;61:297-304.
  • Alegre E, Sammamed M, Fernández-Landázuri S, Zubiri L, González Á. Circulating Biomarkers in Malignant Melanoma. Adv Clin Chem. 2015;69:47-89.
  • Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25:486-95.
  • Alegre E, Zubiri L, Perez-Gracia JL, González-Cao M, Soria L, Martín-Algarra S, González A. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin Chim Acta 2016;454:28-32.
  • Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.
  • Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology. In press.

 

Scientific Shorts